The Effects of Diabetic Duration on Lacrimal Functional Unit in Patients with Type II Diabetes

Table 3

Ocular surface clinical parameters in diabetic patients and normal controls.

Parameters	Controls	Diabetic patients
		<10 y	10∼20 y	≥21 y	Total
SPEED	5.24 ± 3.04	7.25 ± 2.99	6.56 ± 3.48	6.21 ± 3.10	6.68 ± 3.24
LLT (nm)	75.96 ± 19.79	70.71 ± 20.15	73.69 ± 22.07	66.71 ± 16.98	71.04 ± 20.46
Blinks (times)	4.43 ± 3.57	4.73 ± 4.05	6.23 ± 4.25	4.81 ± 4.28	5.40 ± 4.24
NI-BUT (sec)	9.97 ± 5.19	10.22 ± 6.13	10.02 ± 6.33	8.68 ± 4.85	9.73 ± 5.91
TMH (mm)	0.22 ± 0.86	0.24 ± 0.75	0.24 ± 0.11	0.23 ± 0.81	0.24 ± 0.10
Meiboscore	2.46 ± 0.86	2.84 ± 1.14	3.03 ± 1.13	2.92 ± 1.13	2.94 ± 1.13
SPK score	0.32 ± 0.73	0.64 ± 1.09	0.44 ± 0.69	0.44 ± 0.68	0.50 ± 0.83
Sensitivity	58.19 ± 4.15	57.41 ± 5.04	56.13 ± 5.62	52.81 ± 7.50	55.65 ± 6.24
Schirmer (mm)	9.25 ± 8.07	9.23 ± 7.18	5.73 ± 4.89	5.56 ± 4.20	6.76 ± 5.76

Note. SPEED, standard patient evaluation of eye dryness; LLT, lipid layer thickness; NI-BUT, noninvasive tear film break-up time; TMH, tear meniscus height; meiboscore, total percentage of meibomian gland dropout area in upper and lowers eyelids; SPK score, superficial punctate keratopathy score; sensitivity, corneal sensitivity; Schirmer, Schirmer I test (total tear secretion).